LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International)

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

Sep. 25, 2002

By Nuala Moran

No Comments

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

Sep. 25, 2002

By Nuala Moran

No Comments

LONDON - KS Biomedix Holdings plc agreed to a licensing deal worth up to US$60 million for its TransMID 107 brain cancer treatment with Nycomed Group. (BioWorld International)

CellFactors' Skeletex Displays Ability To Form Bone In Muscle

Sep. 18, 2002

By Nuala Moran

No Comments

UK Stem Cell Bank Established To Manage Cell Research Lines

Sep. 18, 2002

By Nuala Moran

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Articles by Nuala Moran

Vernalis Hoping To Break Even In 2004 With Frovatriptan Success

Vernalis Hoping To Break Even In 2004 With Frovatriptan Success

OGS Restructures To Focus On Storage Disorders, Oncology

Red Cross Speaks Out About Potential Biotechnology Abuse

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

Acambis Completes Manufacture Of First Batch Of Smallpox Vaccine

KS Biomedix, Nycomed Sign Deal For TransMID 107 Cancer Therapy

CellFactors' Skeletex Displays Ability To Form Bone In Muscle

UK Stem Cell Bank Established To Manage Cell Research Lines

Today's news in brief

Today's news in brief

J&J’s Ottava robotic system approved for US pivotal trial

In muscular dystrophies, gene therapies race the clock

‘Evo’ AI can design complete genomes